All research at BC Cancer involving humans or material and information derived from humans must be reviewed and approved by the BC Cancer Research Ethics Board 'REB' before the project can be activated. 

The REB is comprised of members who among them pool extensive experience and knowledge in scientific investigations, cancer research, the experience of cancer patients and the ethical issues raised by research involving humans.

Membership

• Chair: Dr. Karen Gelmon
  
• Vice-Chair:  Dr Vivien Bramwell

Membership lists 

• List 82: Dec 12 2022.pdf
• List 81: Oct 20 2022.pdf
• List 80: September 20 2022.pdf
• List 79: August 15 2022.pdf
• List 78: July 20 2022.pdf
• List 77: Jun 01 2022.pdf
• List 76: May 18 2022.pdf
• List 75: Feb 8 2022.pdf

Compliance assurances

The REB complies with the US Department of Health and Human Services (DHHS) Code of Federal Regulations 45 CFR 46.103. These regulations state that every institution engaged in human subject research supported or conducted by the DHHS must have assurance of compliance approved by the US Office for Human Research Protections (OHRP/FDA.)

Federalwide Assurance (FWA) and Institutional Review Board (IRB) assurances with OHRP/FDA have been obtained for both BC Cancer and the BC Cancer Research Ethics Board (REB). These assurances are listed here (REBs in Canada are referred to as IRBs in the US.)

Institutional Organization: BC Cancer (IORG #IORG0003172) 

Assurance

• Type of Assurance: Federalwide Assurance for "BC Cancer"
  
• Assurance Numbers: FWA00001149
  
• Expiry Date: December 12, 2026
  

Assurance

• Type of Assurance: IRB Assurance for "B.C. Cancer IRB #1"
  
• Assurance Numbers: IRB00003797
  
• Expiry Date: December 27, 2024